In alignment with Good Publication Practice (GPP3) guidelines, Alnylam does not compensate authors for time spent authoring or otherwise developing a publication or preparing for the presentation. Alnylam may only consider funding reasonable and customary publication services rendered and fees incurred by the authors.
To ensure compliance with local laws and regulations (e.g., US Open Payments Act, EFPIA), Alnylam must track and, if applicable, report payments or transfers of value associated with certain activities, including publication support.
Important note on disclosure: Alnylam is committed to transparency in its interactions with healthcare professionals and healthcare organizations/institutions consistent with applicable laws and/or codes of practice applicable to the pharmaceutical industry.
